SlowBull
The Business Brief WEDNESDAY, 2 SEPTEMBER 2026
← All stories
Markets

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

1 source ·1 article ·1h ago

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·1h ago

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.